Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download New Developments In The Pharmacologic Treatment Of Schizophrenia PDF full book. Access full book title New Developments In The Pharmacologic Treatment Of Schizophrenia.
| Author | : |
| Publisher | : |
| Total Pages | : 182 |
| Release | : 1992 |
| Genre | : Antipsychotic drugs |
| ISBN | : |
| Author | : Robert R. Conley |
| Publisher | : Professional Communications |
| Total Pages | : 289 |
| Release | : 2007-03 |
| Genre | : Medical |
| ISBN | : 1932610227 |
A handbook for treating schizophrenia with antipsychotic drugs includes coverage of continuation and maintenance therapy and patient outcomes and economic evaluation data.
| Author | : Jeffrey S. Albert |
| Publisher | : John Wiley & Sons |
| Total Pages | : 565 |
| Release | : 2012-06-06 |
| Genre | : Medical |
| ISBN | : 1118309405 |
New and emerging directions in pharmaceutical research to better treat schizophrenia Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases. Targets and Emerging Therapies for Schizophrenia presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined. With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. Targets and Emerging Therapies for Schizophrenia: Provides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment Draws from chemistry, biology, and pharmacology for more effective drug targeting and discovery Explores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides With Targets and Emerging Therapies for Schizophrenia as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.
| Author | : World Health Organization |
| Publisher | : World Health Organization |
| Total Pages | : 80 |
| Release | : 2009 |
| Genre | : Medical |
| ISBN | : 9241547693 |
This manual attempts to provide simple, adequate and evidence-based information to health care professionals in primary health care especially in low- and middle-income countries to be able to provide pharmacological treatment to persons with mental disorders. The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalized anxiety and sleep disorders; obsessive compulsive disorders and panic attacks; and alcohol and opioid dependence. The annexes provide information on evidence retrieval, assessment and synthesis and the peer view process.
| Author | : Katherine J. Aitchison |
| Publisher | : CRC Press |
| Total Pages | : 152 |
| Release | : 2022-03-26 |
| Genre | : Medical |
| ISBN | : 0429524145 |
The new edition of this popular handbook has been thoroughly updated to include the latest data concerning treatment of first-episode patients. Drawing from their experience, the authors discuss the presentation and assessment of the first psychotic episode and review the appropriate use of antipsychotic agents and psychosocial approaches in effective management. This is an authoritative text written by a team of highly respected authors for psychiatrists, neurologists, primary care practitioners and health care professional working in psychiatry. Drawing from their experience, the presentation and assessment of the first psychotic episode are discussed, details regarding antipsychotic drugs and their appropriate use are reviewed and psychosocial approaches are examined. The resulting book offers a concise and valuable guide to those wishing to review the latest proposals for the treatment of first-episode psychosis supported by up-to-date references, in a single publication.
| Author | : Tatiana V. Lipina |
| Publisher | : Royal Society of Chemistry |
| Total Pages | : 304 |
| Release | : 2015-05-13 |
| Genre | : Medical |
| ISBN | : 1782620265 |
Since the pioneering pharmacotherapy for treatment of schizophrenia in the 1950s by antipsychotics, only a few major innovations have been made, pointing to a general stagnation in the field of pharmacology of schizophrenia. Drug Discovery for Schizophrenia covers new insights in the field of schizophrenia with an aim to advance the understanding of scientists and clinicians in this area and to fuel drug discovery. The book outlines a change in the way schizophrenia is treated by moving away from focusing only on treating symptoms in patients. Innovative drugs emerge from deeper comprehension of the pathological processes that emerge earlier in life, hence, providing strategies for preventative therapy to alter the course of this mental disorder. Amongst other current topics, the book covers new findings in genetics and epigenetics, progress in animal models for schizophrenia and the usage of induced pluripotent stem cells. The combination of these important areas benefit psychiatric neuroscience, filling the gaps in the knowledge of neurobiology of schizophrenia and providing novel perspectives for future drug development.
| Author | : Jeffrey A. Lieberman |
| Publisher | : Oxford University Press |
| Total Pages | : |
| Release | : 2012-04-04 |
| Genre | : Medical |
| ISBN | : 0199938369 |
The body of knowledge that we have accumulated about the causes and nature of schizophrenia is prodigious, and the repertoire of evidence-based treatments is substantial and increasing. Comprehensive Care of Schizophrenia distills this corpus into the essential information that clinicians who care for persons with schizophrenia need to know. The second edition of the popular volume is thoroughly updated, offering new information on the advances in research and management since the first edition was published a decade ago. Chapters are streamlined to keep content as concise as possible, while key sections have been revised and expanded to include new information on drug therapy and advice on patient care. People with schizophrenia can suffer from multiple morbidities and disabilities, and thus may require a variety of treatments, both pharmacological and psychosocial. To cover the complex and growing field of schizophrenia management, renowned psychiatrists Jeffrey Lieberman and Robin Murray have recruited a distinguished group of researchers, practitioners and consumers of mental health care. This guide delves into to all aspects of the clinical management of schizophrenia for both the health care professional who treats patients as well as the researcher interested in the advances made in the field and their clinical application.
| Author | : T. Scott Stroup |
| Publisher | : Cambridge University Press |
| Total Pages | : |
| Release | : 2010-04-01 |
| Genre | : Medical |
| ISBN | : 1139487574 |
Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.
| Author | : A. A. Schiff |
| Publisher | : |
| Total Pages | : 142 |
| Release | : 1985 |
| Genre | : Schizophrenia |
| ISBN | : |
| Author | : |
| Publisher | : |
| Total Pages | : 890 |
| Release | : 2011 |
| Genre | : Schizophrenia |
| ISBN | : |
